Literature DB >> 8241605

Calcium antagonists in the elderly.

J G Kelly1, K O'Malley.   

Abstract

The calcium antagonists are associated with a number of advantages over other antihypertensive agents, such as a lack of metabolic, vascular and respiratory adverse events, yet are effective in reducing blood pressure. The currently available calcium antagonists are widely used, and new members, particularly of the dihydropyridine group, continue to emerge. These agents may well be considered for use in the management of hypertension and angina in elderly people. They undergo significant first-pass metabolism and tend to have high values of hepatic clearance with minimal amounts of unchanged drug in the urine. Plasma concentrations tend to be higher in elderly people and for that reason it may be prudent to initiate therapy with lower dosages. With this caveat, adverse effect profiles seem to be qualitatively and quantitatively similar in younger and older people. At equivalent plasma concentrations, the antihypertensive effect appears similar in young and elderly patients, and clinical studies point to comparable efficacy with other drug classes. Calcium antagonists do not have adverse renal, respiratory, cardiovascular, metabolic or peripheral vascular effects and therefore may be useful in patients with relevant concomitant disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241605     DOI: 10.2165/00002512-199303050-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  44 in total

Review 1.  Calcium antagonists--assessment of side effects.

Authors:  T Thulin
Journal:  Scand J Prim Health Care Suppl       Date:  1990

2.  Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients.

Authors:  P Rizzini; C Castello; S Salvi; G Recchia
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

3.  Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.

Authors:  D R Robertson; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.

Authors:  J K Faulkner; D McGibney; L F Chasseaud; J L Perry; I W Taylor
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

5.  Effect of age and high blood pressure on baroreflex sensitivity in man.

Authors:  B Gribbin; T G Pickering; P Sleight; R Peto
Journal:  Circ Res       Date:  1971-10       Impact factor: 17.367

Review 6.  Calcium antagonists in elderly and black hypertensive patients. Therapeutic controversies.

Authors:  W Zing; R K Ferguson; P H Vlasses
Journal:  Arch Intern Med       Date:  1991-11

7.  Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.

Authors:  D R Abernethy; J Gutkowska; L M Winterbottom
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

8.  The relationship between age and relaxation of vascular smooth muscle in the rabbit and rat.

Authors:  J H Fleisch; C S Hooker
Journal:  Circ Res       Date:  1976-04       Impact factor: 17.367

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  A comparison of long acting nifedipine and enalapril in elderly hypertensives: a randomised, single-blind, cross-over study.

Authors:  N L Gilchrist; M G Nicholls; T C Ewer; J H Livesey; R Sainsbury
Journal:  J Hum Hypertens       Date:  1988-06       Impact factor: 3.012

View more
  2 in total

1.  In vivo specific binding characteristics and pharmacokinetics of a 1,4-dihydropyridine calcium channel antagonist in the senescent mouse brain.

Authors:  S Uchida; S Yamada; Y Deguchi; M Yamamoto; R Kimura
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

Review 2.  Optimal treatment of angina in older patients.

Authors:  R N Doughty; N Sharpe
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.